Viswanathan et al., revealed that exenatide successfully manages T2D in individuals with obesity who are insulin-dependent, resulting in lowered C-reactive protein (CRP) and other metabolic parameters, including HbAlc, systolic blood pressure, and TG [122]. This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.